



FORM PTO-1449 IRSY. 7.801 U.S. Department of Commerce Patent and Trademark Office	ATTORNEY DOCKET NO.	601-1-134PCTUS
	SERIAL NO.	10/521,841
LIST OF DOCUMENTARY INFORMATION CITED BY APPLICANT <b>INFORMATION DISCLOSURE STATEMENT</b>	APPLICANT	WIEDER, Robert
	FILING DATE	July 27, 2005
	GROUP	1609

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION YES NO

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

		TITLE:
/M.N./	AA	Korah, et al., Integrin $\alpha 5 \beta 1$ Promotes Survival of Growth-Arrested Breast Cancer Cells: An <i>in Vitro</i> Paradigm for Breast Cancer Dormancy in Bone Marrow, <i>Cancer Research</i> , 64: 4514-4522 (2004)
/M.N./	AB	Stoeltzing et al., Inhibition of Integrin $\alpha 5 \beta 1$ Function with a Small Peptide (ATN-161) Plus Continuous 5-Fu Infusion Reduces Colorectal Liver Metastases and Improves Survival in Mice, <i>Int. J. Cancer</i> , 104: 496-503 (2003)
/M.N./	AC	Khalil et al., A Non-RGD-based Integrin Binding Peptide (ATN-161) Blocks Breast Cancer Growth and Metastasis <i>in vivo</i> . <i>Mol. Cancer Ther</i> , 5:2271-2280 (2006)
/M.N./	AD	Braun, et al., Lack of Effect of Adjuvant Chemotherapy on the Elimination of Single Dormant Tumor Cells in Bone Marrow of High-Risk Breast Cancer Patients, <i>J. Clinical Oncology</i> , 18:80-86 (2000)
/M.N./	AE	Braun, et al., Cytokeratin-Positive Cells in the Bone Marrow and Survival of Patients with Stage I, II or III Breast Cancer, <i>New England Journal of Medicine</i> , 342: 525-534 (2000)

[illegible]